Hepatitis C - Pipeline Review, H2 2012


#135142

273pages

Global Markets Direct

$ 2500

In Stock


Hepatitis C Pipeline Review, H2 2012

Global Markets Directs, 'Hepatitis C Pipeline Review, H2 2012', provides an overview of the Hepatitis C therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. 'Hepatitis C Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hepatitis C.
  • A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hepatitis C.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Hepatitis C therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hepatitis C Therapeutic Products under Development, Key Players in Hepatitis C Therapeutics, Hepatitis C Pipeline Overview, Hepatitis C Pipeline, Hepatitis C Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Hepatitis C Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Hepatitis C 14
Hepatitis C Therapeutics under Development by Companies 16
Hepatitis C Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 29
Comparative Analysis 29
Mid Clinical Stage Products 30
Comparative Analysis 30
Early Clinical Stage Products 31
Comparative Analysis 31
Discovery and Pre-Clinical Stage Products 32
Comparative Analysis 32
Hepatitis C Therapeutics Products under Development by Companies 33
Hepatitis C Therapeutics Products under Investigation by Universities/Institutes 49
Companies Involved in Hepatitis C Therapeutics Development 53
Bristol-Myers Squibb Company 53
Boehringer Ingelheim GmbH 54
F. Hoffmann-La Roche Ltd. 55
Abbott Laboratories 56
United Therapeutics Corporation 57
Medgenics Inc. 58
Valeant Pharmaceuticals International 59
GlaxoSmithKline plc 60
Tekmira Pharmaceuticals Corp. 61
Inovio Biomedical Corporation 62
Idenix Pharmaceuticals, Inc. 63
Gilead Sciences, Inc. 64
Merck & Co., Inc. 65
Lentigen Corporation 66
BioLineRx, Ltd. 67
Ambrilia Biopharma Inc. 68
Biotron Limited 69
Novartis AG 70
Achillion Pharmaceuticals, Inc. 71
InterMune, Inc. 72
Ono Pharmaceutical Co., Ltd. 73
Pfizer Inc. 74
SuperGen, Inc. 75
Toyama Chemical Co. Ltd 76
Vertex Pharmaceuticals Incorporated 77
Genmab A/S 78
Santaris Pharma A/S 79
Tacere Therapeutics, Inc. 80
Alfacell Corporation 81
Crucell N.V. 82
Celgene Corporation 83
4SC AG 84
Hemispherx Biopharma, Inc. 85
Immtech Pharmaceuticals, Inc. 86
Can-Fite BioPharma Ltd. 87
Ligand Pharmaceuticals Incorporated 88
Medivir AB 89
Biota Holdings Limited 90
NanoViricides, Inc. 91
Novelos Therapeutics, Inc. 92
Patrys Limited 93
Peregrine Pharmaceuticals, Inc. 94
Amarillo Biosciences, Inc. 95
BioCryst Pharmaceuticals, Inc. 96
Flamel Technologies S.A. 97
Transgene SA 98
Lipoxen PLC 99
Bukwang Pharmaceutical Co., Ltd. 100
Miraca Holdings Inc. 101
Hanall Pharmaceutical Co., Ltd. 102
Samaritan Pharmaceuticals, Inc. 103
LTT Bio-Pharma Co., Ltd. 104
Summit Corporation plc 105
Phynova Group Ltd 106
Tripep AB 107
Digna Biotech, S.L. 108
Debiopharm Group 109
Immune Network Research Ltd. 110
StemCells, Inc. 111
Maywufa Company Limited 112
SCYNEXIS, Inc. 113
Nutri Pharma ASA 114
Biolex Therapeutics, Inc. 115
Cytheris SA 116
Altor BioScience Corporation 117
Eiger BioPharmaceuticals, Inc. 118
AiCuris GmbH & Co. KG 119
Okairos 120
PTC Therapeutics, Inc. 121
Conatus Pharmaceuticals Inc. 122
Presidio Pharmaceuticals, Inc. 123
Romark Laboratories, L.C. 124
Chimerix, Inc. 125
Phage Biotechnology Corporation 126
Intarcia Therapeutics, Inc. 127
Biotica Technology Ltd 128
Sinovac Biotech Ltd. 129
VLST Corporation, Inc. 130
Virobay Inc. 131
Concert Pharmaceuticals, Inc. 132
Implicit Bioscience Limited 133
Bolder Biotechnology, Inc. 134
Oncolys BioPharma Inc. 135
Globeimmune, Inc. 136
Immunocore Limited. 137
Enanta Pharmaceuticals, Inc. 138
Canopus BioPharma Incorporated 139
PepTcell Limited 140
Arisyn Therapeutics Inc. 141
Jenken Biosciences, Inc 142
Epiphany Biosciences, Inc. 143
GenPhar, Inc. 144
Beckpharma Limited 145
CureTech Ltd. 146
TaiGen Biotechnology Co., Ltd. 147
PharmaEssentia Corporation 148
NasVax Ltd. 149
Regulus Therapeutics Inc. 150
Ascendis Pharma A/S 151
Biopartners Holdings AG 152
Therapure Biopharma Inc. 153
VectorLogics, Inc. 154
iTherX Pharmaceuticals Inc. 155
VLP Biotech, Inc. 156
Hepatitis C Therapeutics Assessment 157
Assessment by Monotherapy Products 157
Assessment by Combination Products 158
Assessment by Route of Administration 159
Assessment by Molecule Type 161
Drug Profiles 163
Vaniprevir - Drug Profile 163
BI 201335 - Drug Profile 164
Alferon N Injection - Drug Profile 166
simeprevir - Drug Profile 167
Asunaprevir - Drug Profile 169
Consensus Interferon + Ribavirin - Drug Profile 171
Infliximab + Pegintron + Ribavirin - Drug Profile 173
AdoMet + Betaine + Pegylated Interferon Alpha 2b + Ribavirin - Drug Profile 175
TMC435 + PEGIFNalpha-2A + Ribavirin - Drug Profile 177
Daclatasvir - Drug Profile 179
BMS-790052 + BMS-650032 - Drug Profile 181
BMS-790052 + BMS-650032 + Pegylated-Interferon Alpha + Ribavirin - Drug Profile 182
Victrelis + Peginterferon Alfa-2b + Ribavirin - Drug Profile 184
Boceprevir + Peginterferon Alfa-2b + Ribavirin + Erythropoietin - Drug Profile 186
Peginterferon Alfa-2a + Ribavirin - Drug Profile 188
Peginterferon Alpha-2a + Ribavirin + Meloxicam - Drug Profile 189
MK7009 + Pegintron + Rebetol - Drug Profile 191
Interferon Alpha-2b + Ribavirin + Interferon-Gamma - Drug Profile 194
Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile 196
Pegaferon + Ribavirin - Drug Profile 198
Intron A + Ribavirin - Drug Profile 199
Nitazoxanide - Drug Profile 200
Pioglitazone + Pegylated Interferon + Ribavirin - Drug Profile 202
BI 201335 + Pegylated Interferon Alpha + Ribavirin - Drug Profile 204
Peginterferon Alfa-2b + Ribavirin + Vitamin D - Drug Profile 205
BMS-914143 + BMS-790052 + Ribavirin - Drug Profile 206
GS-7977 - Drug Profile 208
BMS-790052 + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile 210
Nitazoxanide + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile 212
Silymarin - Drug Profile 214
PSI-7977 + Ribavirin - Drug Profile 215
Ribavirin + Peginterferon Alpha-2a - Drug Profile 217
Peginterferon Alfa 2a + Ribavirin - Drug Profile 219
Hepatitis C Therapeutics Drug Profile Updates 220
Hepatitis C Therapeutics Discontinued Products 242
Hepatitis C Therapeutics - Dormant Products 249
Hepatitis C Product Development Milestones 262
Featured News & Press Releases 262

Appendix 270
Methodology 270
Coverage 270
Secondary Research 270
Primary Research 270
Expert Panel Validation 270
Contact Us 271
Disclaimer 271

Number of Products Under Development for Hepatitis C, H2 2012 16
Products under Development for Hepatitis C Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Development by Companies, H2 2012 (Contd..4) 23
Number of Products under Development by Companies, H2 2012 (Contd..5) 24
Number of Products under Development by Companies, H2 2012 (Contd..6) 25
Number of Products under Development by Companies, H2 2012 (Contd..7) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 30
Comparative Analysis by Late Stage Development, H2 2012 31
Comparative Analysis by Mid Clinical Stage Development, H2 2012 32
Comparative Analysis by Early Clinical Stage Development, H2 2012 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 34
Products under Development by Companies, H2 2012 35
Products under Development by Companies, H2 2012 (Contd..1) 36
Products under Development by Companies, H2 2012 (Contd..2) 37
Products under Development by Companies, H2 2012 (Contd..3) 38
Products under Development by Companies, H2 2012 (Contd..4) 39
Products under Development by Companies, H2 2012 (Contd..5) 40
Products under Development by Companies, H2 2012 (Contd..6) 41
Products under Development by Companies, H2 2012 (Contd..7) 42
Products under Development by Companies, H2 2012 (Contd..8) 43
Products under Development by Companies, H2 2012 (Contd..9) 44
Products under Development by Companies, H2 2012 (Contd..10) 45
Products under Development by Companies, H2 2012 (Contd..11) 46
Products under Development by Companies, H2 2012 (Contd..12) 47
Products under Development by Companies, H2 2012 (Contd..13) 48
Products under Development by Companies, H2 2012 (Contd..14) 49
Products under Development by Companies, H2 2012 (Contd..15) 50
Products under Investigation by Universities/Institutes, H2 2012 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 54
Bristol-Myers Squibb Company, H2 2012 55
Boehringer Ingelheim GmbH, H2 2012 56
F. Hoffmann-La Roche Ltd., H2 2012 57
Abbott Laboratories, H2 2012 58
United Therapeutics Corporation, H2 2012 59
Medgenics Inc., H2 2012 60
Valeant Pharmaceuticals International, H2 2012 61
GlaxoSmithKline plc, H2 2012 62
Tekmira Pharmaceuticals Corp., H2 2012 63
Inovio Biomedical Corporation, H2 2012 64
Idenix Pharmaceuticals, Inc., H2 2012 65
Gilead Sciences, Inc., H2 2012 66
Merck & Co., Inc., H2 2012 67
Lentigen Corporation, H2 2012 68
BioLineRx, Ltd., H2 2012 69
Ambrilia Biopharma Inc., H2 2012 70
Biotron Limited, H2 2012 71
Novartis AG, H2 2012 72
Achillion Pharmaceuticals, Inc., H2 2012 73
InterMune, Inc., H2 2012 74
Ono Pharmaceutical Co., Ltd., H2 2012 75
Pfizer Inc., H2 2012 76
SuperGen, Inc., H2 2012 77
Toyama Chemical Co. Ltd, H2 2012 78
Vertex Pharmaceuticals Incorporated, H2 2012 79
Genmab A/S, H2 2012 80
Santaris Pharma A/S, H2 2012 81
Tacere Therapeutics, Inc., H2 2012 82
Alfacell Corporation, H2 2012 83
Crucell N.V., H2 2012 84
Celgene Corporation, H2 2012 85
4SC AG, H2 2012 86
Hemispherx Biopharma, Inc., H2 2012 87
Immtech Pharmaceuticals, Inc., H2 2012 88
Can-Fite BioPharma Ltd., H2 2012 89
Ligand Pharmaceuticals Incorporated, H2 2012 90
Medivir AB, H2 2012 91
Biota Holdings Limited, H2 2012 92
NanoViricides, Inc., H2 2012 93
Novelos Therapeutics, Inc., H2 2012 94
Patrys Limited, H2 2012 95
Peregrine Pharmaceuticals, Inc., H2 2012 96
Amarillo Biosciences, Inc., H2 2012 97
BioCryst Pharmaceuticals, Inc., H2 2012 98
Flamel Technologies S.A., H2 2012 99
Transgene SA, H2 2012 100
Lipoxen PLC, H2 2012 101
Bukwang Pharmaceutical Co., Ltd., H2 2012 102
Miraca Holdings Inc., H2 2012 103
Hanall Pharmaceutical Co., Ltd., H2 2012 104
Samaritan Pharmaceuticals, Inc., H2 2012 105
LTT Bio-Pharma Co., Ltd., H2 2012 106
Summit Corporation plc, H2 2012 107
Phynova Group Ltd, H2 2012 108
Tripep AB, H2 2012 109
Digna Biotech, S.L., H2 2012 110
Debiopharm Group, H2 2012 111
Immune Network Research Ltd., H2 2012 112
StemCells, Inc., H2 2012 113
Maywufa Company Limited, H2 2012 114
SCYNEXIS, Inc., H2 2012 115
Nutri Pharma ASA, H2 2012 116
Biolex Therapeutics, Inc., H2 2012 117
Cytheris SA, H2 2012 118
Altor BioScience Corporation, H2 2012 119
Eiger BioPharmaceuticals, Inc., H2 2012 120
AiCuris GmbH & Co. KG, H2 2012 121
Okairos, H2 2012 122
PTC Therapeutics, Inc., H2 2012 123
Conatus Pharmaceuticals Inc., H2 2012 124
Presidio Pharmaceuticals, Inc., H2 2012 125
Romark Laboratories, L.C., H2 2012 126
Chimerix, Inc., H2 2012 127
Phage Biotechnology Corporation, H2 2012 128
Intarcia Therapeutics, Inc., H2 2012 129
Biotica Technology Ltd, H2 2012 130
Sinovac Biotech Ltd., H2 2012 131
VLST Corporation, Inc., H2 2012 132
Virobay Inc., H2 2012 133
Concert Pharmaceuticals, Inc., H2 2012 134
Implicit Bioscience Limited, H2 2012 135
Bolder Biotechnology, Inc., H2 2012 136
Oncolys BioPharma Inc., H2 2012 137
Globeimmune, Inc., H2 2012 138
Immunocore Limited., H2 2012 139
Enanta Pharmaceuticals, Inc., H2 2012 140
Canopus BioPharma Incorporated, H2 2012 141
PepTcell Limited, H2 2012 142
Arisyn Therapeutics Inc., H2 2012 143
Jenken Biosciences, Inc, H2 2012 144
Epiphany Biosciences, Inc., H2 2012 145
GenPhar, Inc., H2 2012 146
Beckpharma Limited, H2 2012 147
CureTech Ltd., H2 2012 148
TaiGen Biotechnology Co., Ltd., H2 2012 149
PharmaEssentia Corporation, H2 2012 150
NasVax Ltd., H2 2012 151
Regulus Therapeutics Inc., H2 2012 152
Ascendis Pharma A/S, H2 2012 153
Biopartners Holdings AG, H2 2012 154
Therapure Biopharma Inc., H2 2012 155
VectorLogics, Inc., H2 2012 156
iTherX Pharmaceuticals Inc., H2 2012 157
VLP Biotech, Inc., H2 2012 158
Assessment by Monotherapy Products, H2 2012 159
Assessment by Combination Products, H2 2012 160
Assessment by Stage and Route of Administration, H2 2012 162
Assessment by Stage and Molecule Type, H2 2012 164
Hepatitis C Therapeutics Drug Profile Updates 222
Hepatitis C Therapeutics Discontinued Products 244
Hepatitis C Therapeutics Discontinued Products (Contd..1) 245
Hepatitis C Therapeutics Discontinued Products (Contd..2) 246
Hepatitis C Therapeutics Discontinued Products (Contd..3) 247
Hepatitis C Therapeutics Discontinued Products (Contd..4) 248
Hepatitis C Therapeutics Discontinued Products (Contd..5) 249
Hepatitis C Therapeutics Discontinued Products (Contd..6) 250
Hepatitis C Therapeutics Dormant Products 251
Hepatitis C Therapeutics Dormant Products (Contd..1) 252
Hepatitis C Therapeutics Dormant Products (Contd..2) 253
Hepatitis C Therapeutics Dormant Products (Contd..3) 254
Hepatitis C Therapeutics Dormant Products (Contd..4) 255
Hepatitis C Therapeutics Dormant Products (Contd..5) 256
Hepatitis C Therapeutics Dormant Products (Contd..6) 257
Hepatitis C Therapeutics Dormant Products (Contd..7) 258
Hepatitis C Therapeutics Dormant Products (Contd..8) 259
Hepatitis C Therapeutics Dormant Products (Contd..9) 260
Hepatitis C Therapeutics Dormant Products (Contd..10) 261
Hepatitis C Therapeutics Dormant Products (Contd..11) 262
Hepatitis C Therapeutics Dormant Products (Contd..12) 263
Number of Products under Development for Hepatitis C, H2 2012 16
Products under Development for Hepatitis C - Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 27
Late Stage Products, H2 2012 31
Mid Clinical Stage Products, H2 2012 32
Early Clinical Stage Products, H2 2012 33
Discovery and Pre-Clinical Stage Products, H2 2012 34
Assessment by Monotherapy Products, H2 2012 159
Assessment by Combination Products, H2 2012 160
Assessment by Route of Administration, H2 2012 161
Assessment by Stage and Route of Administration, H2 2012 162
Assessment by Molecule Type, H2 2012 163
Assessment by Stage and Molecule Type, H2 2012 164